ASEPA NEWS

ASEPA NEWSLETTERS

​​

July 2024 Newsletter

January 2024 Newsletter

August 2023 Newsletter

March 2023 Newsletter

July 2022 Newsletter

January 2022 Newsletter

July 2021 Newsletter

January 2021 Newsletter

July 2020 Newsletter

January 2020 Newsletter
July 2019 Newsletter

January 2019 Newsletter​

​

​

RECENT NEWS

 

December 2023:

Newly Generic Oral Diabetes Medications, Saxagliptin and ertugliflozin are now available generic.

https://diabetes.acponline.org/archives/2023/11/10/9.htm 

​

June 2023:

Empagliflozin is now approved in kids with T2DM down to age 10. https://www.medscape.com/viewarticle/993480?src=FYE

​

The FDA and Novo Nordisk warn of Counterfeit Semaglutide pens: 

https://www.pharmacytimes.com/view/fda-novo-nordisk-warn-of-counterfeit-semaglutide-injection-pens?utm_source=sfmc&utm_medium=email&utm_campaign=06222023_VII-23-PHD0542_ViiV_HIV%20PrEP%20RC_Daily_4%20of%208&eKey=YXNobHluLnNtaXRoLnBhQGdtYWlsLmNvbQ==

​

Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg is now available for treatment of pediatric patients aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone (GH). And for the replacement of endogenous GH in adults with growth hormone deficiency (GHD).

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-weekly-therapy-adult-growth-hormone-deficiency

​​​

​

​